Gliclapack MV 0.3mg/500mg/80mg Tablet
Marketer
Koye Pharmaceuticals Pvt ltd
Salt Composition
Voglibose (0.3mg) + Metformin (500mg) + Gliclazide (80mg)
Overview Gliclapack MV 0.3mg/500mg/80mg Tablet
Gliclapack MV 0.3mg/500mg/80mg tablets are classified as antidiabetic medications, a combination therapy for adult type 2 diabetes. This medication aids in blood glucose regulation. Administer Gliclapack MV 0.3mg/500mg/80mg tablets with food, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may adjust based on blood sugar monitoring. Continued use is crucial; discontinuation without medical consultation risks elevated blood glucose, potentially leading to kidney complications, vision impairment, neuropathy, and limb loss. This medication complements a comprehensive diabetes management plan including diet, exercise, and weight management as directed by your doctor. Lifestyle modifications are essential for diabetes control. Hypoglycemia (low blood sugar) is the most prevalent adverse effect, characterized by symptoms like sweating, dizziness, headache, and tremors. Regular meals and readily available glucose sources (e.g., sugary foods or juice) are crucial for prevention. Alcohol consumption should be limited due to its potential to exacerbate hypoglycemia. Additional possible side effects include altered taste perception, nausea, vomiting, diarrhea, abdominal discomfort, headache, edema, blurred vision, and fractures. Weight gain may occur. Contraindications include type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Prior heart disease should be disclosed to your physician before commencing treatment. Pregnant or lactating individuals require medical consultation prior to use. Regular blood glucose monitoring, along with periodic blood tests to assess blood cell counts and liver function, are recommended.
Uses of Gliclapack MV 0.3mg/500mg/80mg Tablet
Managing type 2 diabetes
Major Benefits of Gliclapack MV 0.3mg/500mg/80mg Tablet:
Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Gliclapack MV 0.3mg/500mg/80mg tablets should be administered with a meal.
Common Side effects of Gliclapack MV 0.3mg/500mg/80mg Tablet:
- Nausea
- Hypoglycemia (low blood glucose level)
- Abdominal pain
- Constipation
How to use Gliclapack MV 0.3mg/500mg/80mg Tablet:
Consume this medication precisely as prescribed by your physician, adhering to both dosage and treatment length. Ingest the entire tablet; do not chew, pulverize, or fracture it. It is recommended to take the Gliclapack MV 0.3mg/500mg/80mg tablet with a meal.
How Gliclapack MV 0.3mg/500mg/80mg Tablet works:
Gliclapack MV tablets, containing 0.3mg/500mg/80mg of a triple-action antidiabetic formulation, combine three distinct medications.
SAFETY ADVICE
AlcoholUNSAFE
Combining Gliclapack MV 0.3mg/500mg/80mg tablets with alcohol is hazardous.
PregnancyCONSULT YOUR DOCTOR
The use of Gliclapack MV 0.3mg/500mg/80mg tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible risks prior to prescribing this medication. Seek medical advice before taking this drug.
Breast feedingCAUTION
The use of Gliclapack MV 0.3mg/500mg/80mg tablets during lactation requires careful consideration. Mothers should discontinue breastfeeding throughout their treatment course and until the medication is fully cleared from their system.
DrivingCAUTION
Impaired driving is possible with abnormally low or high blood sugar levels. Refrain from driving if such symptoms arise.
KidneyCAUTION
Patients with kidney impairment should use the 0.3mg/500mg/80mg Gliclapack MV tablet cautiously, potentially requiring dose modification. Physician consultation is recommended. For individuals with severe kidney disease, this medication is contraindicated. Close monitoring of kidney function is advised during treatment.
LiverCAUTION
Patients with liver disease should use Gliclapack MV 0.3mg/500mg/80mg tablets cautiously, potentially requiring dosage modification. Medical advice is necessary. For those with mild to moderate liver impairment, a low initial dose is typically recommended; however, it's contraindicated in patients with severe liver disease.
What if you forget to take Gliclapack MV 0.3mg/500mg/80mg Tablet :
NA
Facts to Know About Gliclapack MV 0.3mg/500mg/80mg Tablet
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
3,018 People bought this recently